Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03661229
Other study ID # 112553
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date October 21, 2018
Est. completion date October 8, 2020

Study information

Verified date August 2021
Source Lawson Health Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients on hemodialysis treatment experience increased levels of cardiovascular disease. In this study, investigators will be detecting hemodialysis induced circulatory stress using the CVInsight Patient Monitoring & Informatics System - InteloMed. This system consists of the CVInsight non-contact device and the CVInsight contact device that measures a patient's response to dialysis by looking at many physiological parameters such as heart rate, heart rate variability, respiratory rate, and how much oxygen the blood is carrying. Investigators would like to validate the mobile CVInsight non-contact device to the currently used standard CVInsight contact device to provide healthcare providers with a better understanding of its role in early detection of cardiovascular stress induced by hemodialysis.


Description:

This observational validation trial involves patients from the prevalent dialysis population in London, Ontario. Investigators intend to validate the mobile CVInsight non-contact device to the standard contact version of this device for assessing hemodialysis induced circulatory stress. The CVInsight Patient Monitoring & Informatics System records a patient's pulse waveform to determine a patient's response to dialysis and alerts to several physiologic changes including pulse strength, pulse rate, pulse irregularity, oxygen saturation, and oxygen saturation variability. The CVInsight contact and non-contact devices will be used for two study visits. The first study visit will be on the patient's first dialysis session of the week (after the weekend - 72 hour inter-dialytic period) and the second study visit will be during the patient's second dialysis session of the week (mid week - 48 hour inter-dialytic period). This will allow investigators to see if there is a difference between these two intervals of time. The investigators will also be using other gold standard methods of validating components of this device including myocardial stunning using the GE Healthcare Vivid q cardiovascular ultrasound system. The echocardiographic ultrasound machine and finometer will be used for two study visits to take place during the patients' regularly scheduled dialysis sessions. The first echocardiogram will be done prior to the initiation of dialysis and the second at peak dialysis stress, which is 15 minutes before the end of the hemodialysis treatment. In addition, the finometer will be used continuously throughout hemodialysis.Validating the mobile CVInsight non-contact device to the CVInsight contact device will allow investigators to observe the degree to which these devices are able to detect hemodialysis induced circulatory stress, which will enable the healthcare provider to detect injury early enough to intervene prior to its occurrence. This is important because hemodialysis and the accompanying stress it induces increases mortality significantly in this population of patients. This study is investigator initiated and the study will continue until the investigators reach our target sample size. Each patient will have two study visits. Patients on a Monday, Wednesday, and Friday schedule will have study visits on Monday and Wednesday of the same week and patients on a Tuesday, Thursday, and Saturday schedule will have study visits on Tuesday and Thursday of the same week.


Recruitment information / eligibility

Status Terminated
Enrollment 14
Est. completion date October 8, 2020
Est. primary completion date October 8, 2020
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Patients receiving conventional thrice weekly maintenance HD - Age =18 years - Able to provide informed consent Exclusion Criteria: • Not meeting inclusion criteria

Study Design


Related Conditions & MeSH terms


Intervention

Device:
CVInsight Monitoring
All participants (n=50) will receive CVInsight non-contact device and CVInsight contact device application during two of their regularly scheduled dialysis sessions.

Locations

Country Name City State
Canada London Health Sciences Centre London Ontario

Sponsors (2)

Lead Sponsor Collaborator
Lawson Health Research Institute Intelomed, Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mobile CVInsight validation against the CVInsight contact device by recording pulse rate trends Validation of the mobile CVInsight with pulse rate from the CVInsight contact device Through dialysis session, an average of 4 hours for two separate visits within the same week.
Primary Mobile CVInsight validation against the CVInsight contact device by recording pulse strength Validation of the mobile CVInsight with pulse strength (derived from a photoelectric plethysmograph waveform) from the CVInsight contact device Through dialysis session, an average of 4 hours for two separate visits within the same week.
Primary Mobile CVInsight validation against the CVInsight contact device by recording pulse irregularity Validation of the mobile CVInsight with pulse irregularity (derived from the pulse wave signal) from the CVInsight contact device Through dialysis session, an average of 4 hours for two separate visits within the same week.
Primary Mobile CVInsight validation against the CVInsight contact device by recording oxygen saturation Validation of the mobile CVInsight with the percentage of oxygen carried in blood from the CVInsight contact device Through dialysis session, an average of 4 hours for two separate visits within the same week.
Primary Mobile CVInsight validation against the CVInsight contact device by recording oxygen saturation variability Validation of the mobile CVInsight with the oxygen saturation variability (derived from the oximeter signal) from the CVInsight contact device Through dialysis session, an average of 4 hours for two separate visits within the same week.
Secondary Early detection of hemodialysis-induced circulatory stress using the CVInsight System The secondary outcome will be assessment of the contact and non-contact CVInsight devices on hemodialysis induced circulatory stress Through dialysis session, an average of 4 hours for two separate visits within the same week.
Secondary Early detection of hemodialysis-induced circulatory stress using the finometer The secondary outcome will be assessment of the finometer on hemodialysis induced circulatory stress Through dialysis session, an average of 4 hours for two separate visits within the same week.
Secondary Early detection of hemodialysis-induced circulatory stress using echocardiography The secondary outcome will be assessment of echocardiography on hemodialysis induced circulatory stress Before the dialysis session and 15 minutes prior to the end of the dialysis session for two separate visits within the same week.
See also
  Status Clinical Trial Phase
Completed NCT04087213 - Study of HemoCare™ Hemodialysis System for Home Nocturnal Dialysis in Patients With ESRD N/A
Completed NCT02207088 - Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease Phase 3
Not yet recruiting NCT03090828 - Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease N/A
Completed NCT02237521 - The Effect of the Incretin Hormones on the Endocrine Pancreatic Function During Hyperglycemia in End-stage Renal Disease N/A
Withdrawn NCT01691196 - Inflammation in Peritoneal Dialysis Patients: Effect of Obesity
Completed NCT01394341 - Liraglutide Treatment to Patients With Severe Renal Insufficiency Phase 4
Active, not recruiting NCT00247507 - The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients Phase 4
Completed NCT00307463 - Effects of Strict Volume Control in Hypertensive Hemodialysis Patients on Cardiac Structure and Chronic Inflammation Phase 4
Recruiting NCT00155363 - Effect of Different Hemodialysis Modality on Adiponectin,Vascular Function and Clinical Prognosis Phase 4
Completed NCT00234156 - The Effect of Fructose on Blood Fats in Dialysis Patients and Healthy Volunteers N/A
Completed NCT00586131 - Arterial pH and Total Body Nitrogen Balances in APD Phase 4
Active, not recruiting NCT05027074 - Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007) Phase 2
Recruiting NCT04575077 - The Role of Hepcidin as a Biomarker to Predict Successful Renal Transplantation
Enrolling by invitation NCT05001009 - Goals of Care Conversations Study N/A
Completed NCT01756508 - Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury Phase 2
Recruiting NCT03862859 - The Danish Warfarin-Dialysis Study - Safety and Efficacy of Warfarin in Patients With Atrial Fibrillation on Dialysis Phase 4
Completed NCT03288922 - Protein-bound Toxin Removal Between Limited Blood Flow Super High-flux Online HDF and High-Efficiency Online HDF N/A
Completed NCT02572882 - Gut Microbiome and p-Inulin in Hemodialysis N/A
Completed NCT02360748 - A Plant Based High Protein Diet to Improve Nutritional Outcomes in Peritoneal Dialysis Patients N/A
Not yet recruiting NCT02238093 - Cardiorenal Syndrome in End-Stage Kidney Disease N/A